Which comes first: atypical antipsychotic treatment or cardiometabolic risk?

  title={Which comes first: atypical antipsychotic treatment or cardiometabolic risk?},
  author={S. Stahl and L. Mignon and J. Meyer},
  journal={Acta Psychiatrica Scandinavica},
  • S. Stahl, L. Mignon, J. Meyer
  • Published 2009
  • Medicine
  • Acta Psychiatrica Scandinavica
  • Objective:  To provide an overview for practicing clinicians on the pharmacological basis of cardiometabolic risk induced by antipsychotic drugs in patients with serious mental illness, to propose hypotheses to explain these risks and to give tips for managing cardiometabolic risk during antipsychotic treatment. 
    232 Citations
    Detecting and Managing Adverse Effects of Antipsychotic Medications: Current State of Play.
    • 17
    Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?
    • 5
    Metabolic syndrome with the atypical antipsychotics.
    • 148


    Metabolic syndrome and schizophrenia.
    • J. Thakore
    • Medicine, Psychology
    • The British journal of psychiatry : the journal of mental science
    • 2005
    • 196
    • Highly Influential
    • PDF
    Atypical antipsychotic‐induced diabetes mellitus: an update on epidemiology and postulated mechanisms
    • 43
    Hyperlipidemia following treatment with antipsychotic medications.
    • 111
    • PDF
    Dyslipidemia Independent of Body Mass in Antipsychotic-Treated Patients Under Real-Life Conditions
    • 102
    • PDF
    Dosing Atypical Antipsychotics
    • 69
    Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    • 169
    Atypical antipsychotic induced weight gain: pathophysiology and management.
    • 40